Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2007-03-13
2007-03-13
Wax, Robert A. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C530S350000
Reexamination Certificate
active
11405095
ABSTRACT:
The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.
REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5206161 (1993-04-01), Drayna et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5474901 (1995-12-01), Drayna et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5525735 (1996-06-01), Gallop et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5549974 (1996-08-01), Holmes
patent: 5569588 (1996-10-01), Ashby et al.
patent: 5593674 (1997-01-01), Drayna et al.
patent: 5593853 (1997-01-01), Chen et al.
patent: 5985562 (1999-11-01), Morser et al.
patent: 6020141 (2000-02-01), Pantoliano et al.
patent: 6036920 (2000-03-01), Pantoliano et al.
patent: 6455294 (2002-09-01), Gan et al.
patent: 6818429 (2004-11-01), Gan et al.
patent: 2003/0017574 (2003-01-01), Gan et al.
patent: 2004/0006205 (2004-01-01), Li et al.
patent: 2005/0042670 (2005-02-01), Gan et al.
patent: 1 531 333 (2003-11-01), None
patent: WO 91/19735 (1991-12-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 93/20242 (1993-10-01), None
patent: WO 98/55645 (1998-12-01), None
patent: WO 00/55180 (2000-09-01), None
patent: WO 00/66717 (2000-11-01), None
patent: WO 02/083841 (2001-10-01), None
patent: WO03/014391 (2002-02-01), None
patent: WO 04/020587 (2004-03-01), None
patent: WO 04/083403 (2004-09-01), None
NCBI Entrez Accession No. 105544 (gi:105544) Eaton, D.L., et al., Aug. 26, 1999.
NCBI Entrez Accession No. AAA60042 (gi:189687) Eaton, D.L., et al., Jan. 7, 1995.
NCBI Entrez Accession No. AAA94971 (gi:1253712) Drayna, D.T., et al., Apr. 3, 1996.
NCBI Entrez Accession No. AAB45836 (gi:1831382) Drayna, D.T., et al., Feb. 7, 1997.
NCBI Entrez Accession No. AAE36249 (gi:10059544) Morser, M.J., et al., Sep. 7, 2000.
NCBI Entrez Accession No. AAP36662 (gi:30584819) Kalnine, N., et al., May 13, 2003.
NCBI Entrez Accession No. AAW13792 (gi:56646729) Gan, W., et al., Dec. 15, 2004.
NCBI Entrez Accession No. AAX29427 (gi:60653465) Hines, L., et al., Mar. 29, 2005.
NCBI Entrez Accession No. AAX29428 (gi:60653467) Hines, L., et al., Mar. 29, 2005.
NCBI Entrez Accession No. CAI10905 (gi:55859590) Griffiths, C., May 18, 2005.
NCBI Entrez Accession No. Q96IY4 (gi:62899885) Eaton, D.L., Feb. 7, 2006.
NCBI Entrez Accession No. XP—007121 (gi:11434004) NCBI Annotation Project, Jul. 16, 2001.
NCBI Entrez Accession No. XP—165638 (gi:20547646) NCBI Annotation Project, May 13, 2002.
Antovic, J.P. et al., “Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation”, Thrombosis Research, vol. 106, pp. 59-62 (2002).
Antovic, J.P. et al., “Does thrombin activatable Fibrinolysis inhibitor (TAFI) Contribute to Impairment of Fibrinolysis in Patients with Preeclampsia and/or Intrauterine Fetal Growth Retardation?”, Thromb Haemost, vol. 88, pp. 644-647 (2002).
Antovic, J.P. et al., “Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?”, Scand J Clin Lab Invest, vol. 64, pp. 745-752 (2004).
Aso, Y. et al., “Metabolic syndrome accompanied by Hypercholesterolemia is strongly associated with Proinflammatory State and Impairment of Fibrinolysis in Patients with type 2 Diabetes”, Diabetes Care, vol. 28(9), pp. 2211-2216 (2005).
Boffa, M.B. et al., “Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells*”, The J. of Biological Chemistry, vol. 278(11), pp. 9250-9257 (2003).
Bouma, B. et al., “Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis”, Pathophysiology of Haemostasis and Thrombosis, vol. 33, pp. 375-381 (2003).
Brouwers, G.J. et al., “Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris”, Thromb Haemost, vol. 90, pp. 92-100 (2003).
Colucci, M. et al., “Deficiency of Thrombin Activatable Fibrinolysis Inhibitor in Cirrhosis is Associated with Increased Plasma Fibrinolysis”, Hepatology, vol. 38, pp. 230-237 (2003).
Donmez, A. et al., “Thrombin activatable fibrinolysis inhibitor in Behçet's disease”, Thrombosis Research, vol. 115, pp. 287-292 (2005).
Dunham, A. et al., “The DNA sequence and analysis of human chromosome 13”, Nature, vol. 428, pp. 522-528 (2004).
Eichinger, S. et al., “Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism”, Blood, vol. 103(10), pp. 3773-3776 (2004).
Hataji, O. et al., “Increased Circulating Levels of Thrombin-activatable Fibrinolysis Inhibitor in Lung Cancer Patients”, American J. of Hematology, vol. 76, pp. 214-219 (2004).
Hori, Y. et al., “Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway”, International J. of Molecular Medicine, vol. 15, pp. 265-268 (2005).
Kochinsky, ML. et al., “Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure”, Clinical Genetics, vol. 60, pp. 345-349 (2001).
Kremer Hovinga, J. et al., “A functional single nucleotide polymorphism in he thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease”, J. of Thrombosis and Haemostasis, vol. 2, pp. 54-57 (2003).
MGC Program Team, “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”, PNAS, vol. 99(26), pp. 16899-16903 (2002).
Maret, D. et al., “Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor”, J. of Thrombosis and Haemostasis, vol. 2, pp. 1969-1979 (2004).
Morange, P.E. et al., “Ala147Thr and C+1542G Polymorphisms in the TAFI gene are not Associated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers”, Thromb Haemost, vol. 86, pp. 1583-1584 (2001).
Morange, P.E. et al., “Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence”, Thromb Haemost, vol. 89, pp. 554-560 (2003).
Morange, P.E. et al., “TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study”, J. of Thrombosis & Haemostasis, vol. 3, pp. 1503-1510 (2005).
Mosnier, L. O. et al., “Identification of thrombin activat
Hsu Mei-Yin
Matsueda Gary R.
Tamura James K.
Bristol--Myers Squibb Company
D'Amico Stephen C.
Noakes Suzanne M.
Wax Robert A.
LandOfFree
Baboon TAFI polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Baboon TAFI polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Baboon TAFI polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794957